Products for Research Use Only

Rabacfosadine (succinate)

CAT: 0804-HY-13640ASize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13640ASize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Rabacfosadine (GS-9219) succinate, a novel proagent of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells[1].
CAS Number
1431856-99-3
Product Name Alternative
GS-9219 (succinate) ; VDC-1101 (succinate)
UNSPSC
12352005
Target
Nucleoside Antimetabolite/Analog
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rabacfosadine-succinate.html
Solubility
10 mM in DMSO
Smiles
OC(CCC(O)=O)=O.CCOC([C@H](C)NP(COCCN1C2=NC(N)=NC(NC3CC3)=C2N=C1)(N[C@@H](C)C(OCC)=O)=O)=O
Molecular Formula
C25H41N8O10P
Molecular Weight
644.61
References & Citations
[1]Reiser H, et al. GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res. 2008 May 1;14 (9) :2824-32.|[2]De Clercq E. Tanovea® for the treatment of lymphoma in dogs. Biochem Pharmacol. 2018 Aug;154:265-269.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2

Chemical Information

Rabacfosadine Succinate

Rabacfosadine Succinate is the succinate form of rabacfosadine, an acyclic nucleotide phosphonate prodrug and polymerase inhibitor that can potentially be used for its antineoplastic activity in the treatment of lymphoma in dogs. Upon administration, rabacfosadine is hydrolyzed intracellularly to 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2, 6-diaminopurine (cPrPMEDAP) and subsequently deaminated to 9-(2-phosphonylmethoxyethyl) guanine (PMEG) and phosphorylated to PMEG diphosphate (PMEGpp). PMEGpp binds to and inhibits DNA polymerases. This inhibits DNA synthesis, resulting in S phase arrest and induction of apoptosis.

CAS Number1431856-99-3
PubChem CID73425536
IUPAC Namebutanedioic acid;ethyl (2S)-2-[[2-[2-amino-6-(cyclopropylamino)purin-9-yl]ethoxymethyl-[[(2S)-1-ethoxy-1-oxopropan-2-yl]amino]phosphoryl]amino]propanoate
Molecular FormulaC25H41N8O10P
Molecular Weight644.6
Topological Polar Surface Area259
Hydrogen Bond Donor Count6
Hydrogen Bond Acceptor Count17
Rotatable Bond Count20
Heavy Atom Count44
Formal Charge0
Complexity852
SMILES
CCOC(=O)[C@H](C)NP(=O)(COCCN1C=NC2=C(N=C(N=C21)N)NC3CC3)N[C@@H](C)C(=O)OCC.C(CC(=O)O)C(=O)O
InChI
InChI=1S/C21H35N8O6P.C4H6O4/c1-5-34-19(30)13(3)27-36(32,28-14(4)20(31)35-6-2)12-33-10-9-29-11-23-16-17(24-15-7-8-15)25-21(22)26-18(16)29;5-3(6)1-2-4(7)8/h11,13-15H,5-10,12H2,1-4H3,(H2,27,28,32)(H3,22,24,25,26);1-2H2,(H,5,6)(H,7,8)/t13-,14-;/m0./s1
InChIKey
XLBDQSJWTNREFA-IODNYQNNSA-N
Chemical Structure
2D Structure
2D structure of Rabacfosadine Succinate
CAS: 1431856-99-3
CID: 73425536
Formula: C25H41N8O10P
MW: 644.6
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight644.6
Hydrogen Bond Donor Count6
Hydrogen Bond Acceptor Count17
Rotatable Bond Count20
Exact Mass644.26832653
Monoisotopic Mass644.26832653
Topological Polar Surface Area259 Ų
Heavy Atom Count44
Formal Charge0
Complexity852
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count2
Compound Is CanonicalizedYes